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 To the Editor, 
 Recently, some concerns have been reported about a tech-
nical bulletin by Roche Diagnostics GmbH (Mannheim, 
Germany) regarding the adjustment to the calibration 
curve of the Elecsys Troponin T high-sensitivity (hs) assay 
[ 1 ]. According to the bulletin, the goal of the manufacturer 
was to recalibrate the control materials of the Troponin T 
hs assays to return to the original assay specifications. The 
revised lots of calibrators (lots 167345 and 167650) should 
yield measurable cardiac troponin T (cTnT) concentra-
tions in a greater proportion of patient samples for which 
the concentrations were undetectable with previous lots, 
including lot 163704 [ 1 ]. This adjustment regarding cali-
bration materials may have major implication for patient 
care, including the recalculation of the 99th percentile 
value for cTnT assay [ 1 ], which is the cornerstone of the 
definition of myocardial infarction [ 2 ]. 
 The aim of the present report is to compare the 
results obtained by measuring several plasma samples 
of healthy subjects and patients with acute or chronic 
cardiac diseases to give the users of Elecsys Troponin 
T hs assay some information on the difference in cTnT 
values measured using the previous and the new recali-
brated lots. 
 From March to June 2012, cTnT was measured with 
the ECLIA method using lot 163704 on 520 heparinized 
plasma samples (collected from 367 healthy subjects 
and 153 patients with acute or chronic cardiac diseases) 
and stored in several aliquots at  − 80 ° C. From October to 
December 2012, we reassayed another aliquot stored at 
 − 80 ° C of the same plasma samples with lot 167345. The 
cTnT was assayed by the ECLIA Troponin T hs method on 
the Cobas e411 platform in accordance with the instruc-
tions provided by the manufacturer [ 3 ]. 
 Patients with acute or chronic cardiac diseases were 
admitted to the clinical wards and the intensive coronary 
unit of the Fondazione Toscana G. Monasterio, Pisa, Italy. 
All healthy people were recruited from the laboratory staff, 
blood donors, or voluntary subjects included in screening 
programs for preventive medicine (also including adoles-
cent subjects). The presence of cardiac or systemic acute 
or chronic diseases was ruled out in all subjects by check-
ing the medical history, accurate clinical examination, 
electrocardiography, cardiac imaging (if needed), and 
laboratory tests. 
 We reported the linear regression analyses among 
the cTnT values measured in 520 samples of healthy sub-
jects and patients with lot 163704 (x-axis) and those with 
lot 167345 (y-axis) in  Figure 1 A. Moreover, we reported 
the regression analysis including only the 367 healthy 
subjects in  Figure 1 B. All samples with measured values 
below 3 ng/L were reported in the figure and considered 
for the statistical analysis as containing 3 ng/L of cTnT. 
Although these data suggest a strict linear relationship 
between the values measured with the two lots, the linear 
regression equation reported in  Figure 1 A does not allow 
a correct estimation of the true difference between cTnT 
concentrations, obtained with the two lots, throughout all 
the working range (from 3 to approx. 25,000 ng/L), espe-
cially when considering the cTnT values in the normal 
range. 
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 On the contrary, the linear regression calculated using 
log-transformed cTnT values allowed a better definition 
and estimation of differences between lots throughout 
all the working range ( Figure 2 ). For example, the linear 
regression of  Figure 2 gives a value of 15.7 ng/L (y-axis) 
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 Figure 1   Linear regression analysis between cTnT values measured with lot 163704 (x-axis) and those with lot 167345 (y-axis). 
 (A) Regression analysis including all plasma samples from healthy subjects and cardiac patients. (B) Regression analysis including only 
healthy subjects. All samples with measured values  < 3 ng/L were reported and considered for the statistical analysis as containing 3 ng/L 
of cTnT (considered as the blank of the method) [ 2 ]. 
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 Figure 2   Linear regression analysis between the log-transformed 
cTnT values measured with lot 163704 (x-axis) and those with lot 
167345 (y-axis). 
 All samples with measured values  < 3 ng/L were reported and 
considered for the statistical analysis as containing 3 ng/L of cTnT 
(considered as the blank of the method) [ 2 ]. 
measured with lot 167345 at the suggested decision level 
of 14 ng/L [ 3 ] measured with lot 163704 (x-axis), whereas 
the corresponding cTnT value (y-axis) calculated from 
the equation reported in  Figure 1 B, which only takes into 
account values ranging from 3 to 22 ng/L, is 13.8 ng/L. 
 The measured 99th percentile values of cTnT concen-
trations of 367 healthy people (also including adolescent 
subjects) were 14.3 ng/L for lot 163704 and 14.9 ng/L for lot 
167345, respectively. Considering only the 173 apparently 
healthy adults (age range, 43 – 76 years; mean ± SD, 59.4 ± 8.0 
years; median, 60.0 years; 25th – 75th percentile, 52.0 – 65.0 
years), the measured 99th percentile value was 16.4 ng/L 
for lot 163704 and 18.4 ng/L for lot 167345. Moreover, in 
the 194 adolescent subjects (age range, 10 – 14 years), all 
the cTnT values measured with lot 163704 were  < 3 ng/L, 
whereas 26 samples showed cTnT values  > 3 ng/L (corre-
sponding to 13% of total) when measured with lot 167345. 
In the 173 apparently healthy adult subjects, 114 samples 
showed cTnT values  < 3 ng/L (i.e., 66% of total) with lot 
163704, whereas only 59 with lot 167345 (i.e., 34% of total; 
p < 0.0001 by  χ 2 -test). 
 The assay reproducibility for the two considered 
reagent lots was similar as shown by internal quality 
control data on the low-level control serum (PC TN1 REF 
05095107 190 PreciControl Troponin by Roche Diagnostics; 
lot 163704: mean cTnT value, 26.9 ng/L; CV, 8.1%; n = 35; 
lot 167345: mean cTnT value, 28.5 ng/L; CV, 7.2 %; n = 120). 
These data also confirm that the recalibrated lot 167345 
gives values higher than the previous one of approximately 
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1.5 ng/L at cTnT concentrations around the decision level. 
Given that lot 163704 is no longer available, we were not 
able to perform a complete imprecision profile for the two 
considered reagent lots; thus, we could not demonstrate if 
the recalibration also had an effect on the LoD of method. 
 Our data indicate that the difference between the 
measured values with the two lots [percent difference 
(mean ± SD), 17.0% ± 43.9%, calculated as (lot 167345-lot 
163704)/lot 163704 × 100], although statistically signifi-
cant, is probably not clinically relevant for the diagnosis 
of acute myocardial infarction (AMI). From a clinical point 
of view, it is important to note that to diagnosis AMI, two 
or more samples are needed to confirm the presence of the 
increase/decrease trend of cTnT values [ 2 ]. As a result, the 
typical pattern of cTnT values in patients with AMI should 
not be substantially affected. 
 If one is interested in the recalculation of some 
plasma samples previously measured with lot 163704, 
the linear regression reported in  Figure 2 can be used for 
this purpose. Considering that the linear relationship is 
very strict (R = 0.992) and the number of samples used 
for the statistical analysis is very high (i.e., n = 520), the 
absolute difference between the values measured with 
the two lots can be accurately estimated using the equa-
tion reported in  Figure 2 . However, our data indicate that 
at very low cTnT concentrations, the recalibration made 
by the manufacturer may have a more relevant clinical 
effect. Indeed, using the recalibrated lot 167345, cTnT can 
be measured with the ECLIA method above the limit of 
blank (i.e., 3 ng/L) [ 3 ] in approximately 66% of apparently 
healthy adults subjects compared with only 34% with lot 
163704. According to the scorecard designation proposed 
by Apple [ 4 ], these data indicate that the ECLIA method, 
which uses the recalibrated lot 167345, should be con-
sidered to be a first-generation high-sensitivity method 
(level 2) for the measurement of cTnT. 
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